In early November 2015, the International Society for Infectious Diseases received an enquiry from a Brazilian man concerned about his pregnant wife's recent Zika like illness and the microcephaly on their current fetal USS; 'I am convinced that there is a relationship and that we are not the only ones'.
At the same time, the Secretariat of Health for Pernambuco State issued an alert based on a 10-fold surge in observed number of microcephaly cases and a suspicion of an infectious cause. By the end of November, Brazil had identified 1248 potential microcephaly cases in 2015, compared with a national annual average of 62 cases per year occurring in the midst of a large Zika virus outbreak.
In February 2016, on the basis of expert advice, the World Health Organisation declared a public health emergency of international concern mobilising a large international research effort to better understand the phenomenon. Prior to this, Zika virus was thought to be of little clinical concern and our understanding of its relevant pathophysiology, diagnostics, therapeutics and vaccinology was and still is extremely limited.
Zika virus is arthropod borne, single-stranded RNA (fully sequenced) virus belonging to the Flaviviridae family, which includes Dengue, West Nile, Yellow Fever and Japanese encephalitis viruses. Two lineages have been determined based on phylogenetic studies, the African and Asian. The Zika virus spreading currently in the Americas is most closely related to the Asian strain, which circulated in French Polynesia during the 2013-2014 outbreak.
Following the isolation of Zika virus was from a rhesus monkey in the Zika Forest, Uganda, in 1947, the first human Zika virus infection was then described in Nigeria a few years later and it has been intermittently isolated from humans in Africa and South East Asia where it is endemic. The potential range of Zika virus is predominantly determined by the distribution of its main mosquito vector, Aedes aegypti. Of note, the vector does not occur at altitudes above 2000 m explaining the absence of Zika virus risk in certain locations in otherwise affected countries.
The first large epidemic was reported in Micronesia in 2007 with three quarters of the population being infected. The virus marched eastwards, hopping across Pacific islands with another large outbreak in French Polynesia in 2013. The virus was first reported in Brazil in 2015, although genetic analysis suggests it may have arrived as early as 2013. Since then, it has continued its relentless march on through South America and eastwards into the Caribbean. At the time of writing, 41 countries have reported active Zika transmission.
The main Zika virus' vector is the daytime biting mosquito Aedes aegypti. Zika infection was a recognised enzootic infection with a mosquito-monkey-mosquito cycle with occasional spillover to the human population. From the first recognised pandemic, the infection has become a human disease with a purely mosquito-human-mosquito cycle. A. albopictus is a less efficient vector but extends the potential range of the epidemic to Europe where this mosquito is already present.
Non-vector transmission has only recently been recognised. Mother to child transmission has been reported both transplacentally with Zika virus RNA being detected in amniotic fluid 1,2 and perinatally by paired blood samples taken from newborn and mothers. A small number of sexually transmitted infections have been reported and viable virus has been detected in semen for several weeks after recovery.
Transmission via blood transfusion has not been documented but Zika virus RNA was detectable in 3% of asymptomatic blood donors during the French Polynesia outbreak, suggesting another possible route of transmission.
Following replication in the epithelial cells of the mosquito's midgut, the virus reaches the salivary gland and is then injected into the skin of a human. The virus initially infects the epidermal keratinocytes, dermal fibroblast and immature dendritic cells and then spreads to lymph nodes and the bloodstream.
Viral neurotropism was first suggested by the detection of virus in the brains of intraperitoneally infected mice in the 1950s. Subsequent studies showed that the virus could infect neurons and glia cells causing cell death and a recent study has suggested a preferential pathogenicity to progenitor neural cells, 3 possibly explaining the rarity of neurological features in adults.
In the majority of infected adults, the infection resolves asymptomatically. Postnatal infection of infants also appears to be clinically mild and transient, but long-term effects have yet to be assessed. For symptomatic individuals, the observed incubation period is 3 to 12 days. Symptoms, when reported, commonly include a macular papular rash, arthralgia, myalgia, conjunctivitis and fever. These are usually mild and self limiting, lasting for 2 to 7 days. Headache and retrorbital pain have also being described. Severe disease requiring hospitalization is exceptional. Neurological manifestations in adults have been documented and cases of peripheral nervous syndromes have been reported but appear to be rare. An association with Guillain-Barre and other autoimmune neurological complications was suspected in previous outbreaks. A case of Zika-associated meningoencephalitis has been recently described and the finding of culturable virus in the CSF supports neurotropism. The epidemiology in endemic areas suggests that once immunity develops it is robust and persists. Latency and recurrence of disease are not expected although the virus may persist for several weeks in semen.
Pregnant women can be infected at any stage of pregnancy and vertical transmission has been documented throughout the pregnancy. There is no evidence that pregnant women are more susceptible to infection or have a more severe illness, but they may be more attractive to mosquitoes. In a prospective cohort study of pregnant women presenting with a rash, the clinical features significantly associated with a confirmed Zika virus infection were presence of conjunctival injection and lymphadenopathy, either localised or generalised. 4 Interestingly, fever was present in only one third of the infected individuals. The nature of the rash was predominantly maculopapular.
In contrast to the transient nature of infection acquired postnatally, infected fetuses appear to produce high levels of detectable virus for a prolonged period, 1 as is also observed for human Cytomegalovirus (CMV) and Rubella virus intra-utero infections.
In the study by Brasil et al., ultrasound (US) abnormalities were detected in 29% of fetuses where the mother had confirmed Zika infection. 4 Several other case reports and case series of microcephaly in relation to the current Zika virus infection in South America have been published. [5] [6] [7] [8] Many reported substantial Central Nervous System (CNS) abnormalities and fetal demise, either in-utero or shortly after birth. Effects included not only microcephaly but also cerebral calcifications (occurring regardless of gestation at infection) severe cortical/subcortical atrophy, agenesis vermis, 4 agyria, 6 oligohydramnios, fetal growth restriction and ocular problems. documentation of redundant scalp skin suggests that brain volume can actually retract in-utero following infection. One study described four cases where the virus was detected only in the brain of the affected neonates, again supporting the neurotropic predilection of this virus. 8 A retrospective review of the 2013-2014 Zika outbreak in the French Polynesia also described 17 cases of congenital brain malformations including microcephaly, although the association with Zika infection was only temporal and maternal infection had not been recorded. 9 Causality of microcephaly has been established for other viruses such as rubella. Rubella infection in pregnancy can cause congenital rubella syndrome (CRS) whose manifestations include microcephaly with cerebral calcifications. Before the widespread use of the vaccine, rubella epidemics were associated with clusters of CRS when the infection was circulating among non-immune pregnant women. With the adoption of universal vaccination during childhood, and the subsequent herd immunity, cases of CRS dropped drastically. The absence of clusters of microcephaly in parts of Africa and Asia can be explained by the majority of the population being immune by the time they reach childbearing age.
Whilst several similarities exist between the current Congenital Zika Syndrome and CRS, in CRS significant abnormalities are observed in multiple organs, whilst in Zika associated reports, almost all abnormalities can be attributed to a neurodevelopmental insult.
The differential diagnosis of a pregnant woman presenting with symptoms compatible with Zika virus infection and evidence of exposure (adequate travel/exposure history) is wide. Given the implications of maternal infection to the fetus, clinicians also clearly need to actively consider rubella, HIV, CMV, syphilis, toxoplasmosis, malaria and parvovirus, depending on features and context. For all of these, a clinical diagnosis remains unreliable and laboratory confirmation should be sought.
The diagnosis of Zika infection relies on the detection of the virus genome during the acute phase of infection by PCR. The virus is detectable for a few days, usually less than five, in blood during the initial symptoms and it is then shed in urine where it may be detectable for up to 2 weeks. Previous routine serological tests were unreliable due to uncertain sensitivity and poor specificity, with considerable cross reactivity with antibodies to other Flaviviruses. This is an area that needs urgent development to enable reliable testing in non-specialist settings.
The mainstay of the management is to avoid being bitten by the Aedes sp mosquito. The World Health Organisation (WHO) recommends wearing light coloured clothing, using a mosquito repellent (DEET, IR 3535 or Icaridin can be used in pregnancy), ensuring protective netting is used if sleeping during the day and eliminating mosquito breeding sites. For women not living in a Zika affected area, WHO, Centre for Disease Control (CDC) and Public Health England (PHE) advise avoiding travelling to a Zika affected area if pregnant.
Because of the potential for sexual transmission guidance also exists for individuals trying to conceive and for male partners of pregnant women who travel to a Zika virus affected area. UK guidelines currently recommend individuals avoid conception and using barrier contraceptives for 1 month after leaving an affected area if asymptomatic and for 6 months if reporting a Zika like illness. This applies to both male and female partners pre-conception and to men with pregnant partners.
For asymptomatic pregnant women with infection risks, international guidance (WHO/CDC/RCOG) recommends monitoring fetal development with US for all pregnant women who have been in/remain in a Zika virus affected area regardless of prior symptoms or tests. The timing and frequency of scans varies from guideline to guideline and reflects differences in available resources and discreet (travellers) versus ongoing risk. It is important to highlight that the absolute risk to the fetus, even to individuals living in an area with an epidemic, appears to be low (1-4/1000 live births in affected Brazilian areas). Where non-diagnostic abnormalities are detected on US, an amniocentesis to look for viral RNA may help inform decisionmaking. It is important that other potential causes of fetal abnormalities are not overlooked.
Pregnant women with suspected or confirmed Zika infection should be monitored by regular US to evaluate fetal development. Until more specific and sensitive tests are available, international recommendations rely heavily on a risk assessment based on clinical and epidemiological features, or the rare situation where detection of Zika virus RNA has confirmed infection. Current data suggest the majority of fetuses will develop normally 4 although long-term neurodevelopmental effects will not be known for some time.
The scientific consensus is now that Zika virus is the cause of the increase in microcephaly cases. Fetal effects appear to be focused on the CNS, are often severe and can occur at any stage of gestation. Accurate data to inform discussions with women on any risk to their pregnancy are currently very limited and will not account for effects that arise postnatally. That said, in highly affected areas, microcephaly was only documented in 1-4/1000 live births and is likely to have been over reported. Diagnosis of infection in adults is hampered by the mild and non-specific clinical features, transient nature of viraemia and lack of sensitive and specific serological assays.
No vaccine or therapeutic agent is available and advice to pregnant women is to prevent the infection by minimising mosquito exposure. Fetal US stands as the main tool for detecting potentially affected fetuses, regardless of previous maternal symptoms, if an infection risk occurred at any stage of pregnancy.
